Literature DB >> 16794758

Prevalence of patients continuing to smoke after vascular interventions.

Afshin Assadian1, Romana Rotter, Christian Senekowitsch, Ojan Assadian, Georg W Hagmüller, Michael Kunze.   

Abstract

INTRODUCTION: Smoking is one of the most important risk factors for the development and progression of atherosclerosis. Smoking cessation is an obligatory element in the management of vascular problems and in patients scheduled for vascular interventions. The aim of this study was to assess the prevalence of patients smoking before and after vascular surgical procedures and to evaluate the requirements for inpatient programs for smoking cessation and nicotine replacement therapy.
METHODS: 500 patients admitted for vascular interventions were included in this prospective study. Smoking status was evaluated both objectively and subjectively. All patients underwent measurements of exhaled breath carbon monoxide to quantify nicotine dependency and all answered a standardized Fagerström questionnaire both on admission and after surgery to identify current smokers.
RESULTS: Of 500 vascular patients included in the study, only 70 (14 %) never had smoked, 243 (49 %) had given up smoking before admission and 161 (32 %) were current smokers. Of the current smokers, 64 (40 %) did not smoke during hospitalization but 97 (60 %) continued to smoke in hospital. Of these 97 patients, 78 (80 %) were men and 19 women; their mean age was 61 +/- 4 years (range 40-84). Four patients had surgery for infrarenal aortic aneurysm, 40 underwent carotid endarterectomy and 53 had peripheral arterial occlusive disease (PAD). There was no difference between abstinent patients and continuing smokers in previous cigarette consumption or Fagerström score, a predictor for long-term smoking behavior. Patients with carotid artery stenosis were significantly more abstinent while hospitalized (P = 0.006); patients with PAD, however, were more likely to continue smoking as inpatients (P = 0.004). Sixty-five percent of continuing smokers stated that they would stop smoking in hospital if counseling and nicotine replacement therapy were provided. With regard to their predominant location of atherosclerosis, patients with PAD were less willing than those with carotid stenosis to abstain from smoking while hospitalized (53 % vs 88 %, respectively; P < 0.001).
CONCLUSION: A substantial proportion of patients admitted for vascular surgery are smokers. More than half of these continue to smoke in the hospital, an environment where smoking is prohibited by law. Counseling, nicotine replacement therapy and smoking-cessation programs are urgently needed for vascular surgical inpatients.

Entities:  

Mesh:

Year:  2006        PMID: 16794758     DOI: 10.1007/s00508-006-0572-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  18 in total

1.  The association between cigarette smoking and abdominal aortic aneurysms.

Authors:  T B Wilmink; C R Quick; N E Day
Journal:  J Vasc Surg       Date:  1999-12       Impact factor: 4.268

2.  Consistency or change in nicotine dependence according to the Fagerström Test for Nicotine Dependence over three years in a population sample.

Authors:  Ulrich John; Christian Meyer; Hans-Jürgen Rumpf; Anja Schumann; Ulfert Hapke
Journal:  J Addict Dis       Date:  2005

3.  Assessment of smoking status in patients with peripheral arterial disease.

Authors:  Simon D Hobbs; Antonius B M Wilmink; Donald J Adam; Andrew W Bradbury
Journal:  J Vasc Surg       Date:  2005-03       Impact factor: 4.268

4.  The effect of cigarette smoking on exercise capacity in patients with intermittent claudication.

Authors:  A W Gardner
Journal:  Vasc Med       Date:  1996       Impact factor: 3.239

5.  The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.

Authors:  A M Joseph; S M Norman; L H Ferry; A V Prochazka; E C Westman; B G Steele; S E Sherman; M Cleveland; D O Antonuccio; D O Antonnucio; N Hartman; P G McGovern
Journal:  N Engl J Med       Date:  1996-12-12       Impact factor: 91.245

6.  Alternative nicotine delivery systems (ANDS)--public health-aspects.

Authors:  U Kunze; R Schoberberger; A Schmeiser-Rieder; E Groman; M Kunze
Journal:  Wien Klin Wochenschr       Date:  1998-12-11       Impact factor: 1.704

7.  Cigarette smoking and peripheral arterial occlusive disease.

Authors:  C W Cole; G B Hill; E Farzad; A Bouchard; D Moher; K Rody; B Shea
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

Review 8.  Clinical and pathophysiological effects of active and passive smoking on the cardiovascular system.

Authors:  B V Taylor; G Y Oudit; P G Kalman; P Liu
Journal:  Can J Cardiol       Date:  1998-09       Impact factor: 5.223

9.  Nicotine dependence: development, mechanisms, individual differences and links to possible neurophysiological correlates.

Authors:  Ernest Groman; Karl Fagerström
Journal:  Wien Klin Wochenschr       Date:  2003-03-31       Impact factor: 1.704

10.  Smoking and growth rate of small abdominal aortic aneurysms.

Authors:  S T MacSweeney; M Ellis; P C Worrell; R M Greenhalgh; J T Powell
Journal:  Lancet       Date:  1994-09-03       Impact factor: 79.321

View more
  3 in total

1.  [Smoking cessation must be professionalized].

Authors:  Michael Kunze; Ernest Groman
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

2.  Utilization of the Electronic Health Record to Improve Provision of Smoking Cessation Resources for Vascular Surgery Inpatients.

Authors:  Brigitte K Smith; Robert T Adsit; Douglas E Jorenby; Jon S Matsumura; Michael C Fiore
Journal:  Int J Cardiovasc Res       Date:  2015-05-30

3.  Nicotine Dependence and the Level of Motivation for Ceasing Smoking in the Case of Patients Undergoing Vascular Surgeries Versus the Optimisation of Perioperative Care-Pilot Survey.

Authors:  Renata Piotrkowska; Wioletta Mędrzycka-Dąbrowska; Piotr Jarzynkowski; Robert Ślusarz
Journal:  Int J Environ Res Public Health       Date:  2022-08-20       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.